Straumann, the Swiss dental implant giant, is sinking $30 million into a low-priced competitor in South Korea with an option to buy a majority stake down the line.
GE Healthcare is looking to cash in on the march toward hospital efficiency. It announced the acquisition of operating room management and analytics solutions provider CHCA Computer Systems today for an undisclosed amount. The deal is expected to close in the second quarter of 2014.
Baxter is buying out collaborator Chatham Therapeutics for $70 million, planning to absorb the gene therapy specialist into its growing hemophilia R&D operation as it prepares to separate its drug and device businesses next year.
Actavis has bagged its latest catch. Fresh off last month's deal to buy Forest Laboratories in a $25 billion deal, the generics maker forked over a much smaller amount--$100 million--to buy a small generics company in Thailand.
Close to a year after Forma Therapeutics' executive team hammered out a partnership with Celgene packed with $200 million in early-stage payouts, the big biotech outfit has come back with a $600 million discovery deal that might eventually lead the pair to the M&A altar.
Johnson & Johnson has formally accepted the Carlyle Group's $4 billion-plus bid to snatch up its Ortho Clinical Diagnostics arm, more than two months after announcing the proposed transaction.
CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.
The day after Baxter announced it will split its biopharma and medical products, an analyst is calling for U.K. devicemaker Smith & Nephew to follow suit.
Baxter International is the latest life sciences player to see better living through mitosis, unveiling a plan to separate its drug development arm from its sprawling med tech business in hopes of helping each grow faster.
Japan is the second largest drug market after the U.S., and Western drugmakers are giving it new attention as growth slows elsewhere. AstraZeneca has upped its bet there, paying Sumitomo Chemical about $102 million to buy full control of its Japanese subsidiary AstraZeneca KK.